Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 21 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.01 Insider Own6.84% Shs Outstand93.27M Perf Week-1.54%
Market Cap880.50M Forward P/E- EPS next Y-2.78 Insider Trans22.65% Shs Float91.66M Perf Month-3.87%
Income-165.03M PEG- EPS next Q-0.55 Inst Own100.84% Short Float11.72% Perf Quarter-14.44%
Sales0.00M P/S- EPS this Y-17.16% Inst Trans8.39% Short Ratio10.07 Perf Half Y13.15%
Book/sh5.36 P/B1.67 EPS next Y-18.67% ROA-30.80% Short Interest10.75M Perf Year-47.32%
Cash/sh5.72 P/C1.57 EPS next 5Y11.00% ROE-34.51% 52W Range6.57 - 22.93 Perf YTD-19.87%
Dividend Est.- P/FCF- EPS past 5Y-11.24% ROI-30.83% 52W High-60.97% Beta1.03
Dividend TTM- Quick Ratio15.03 Sales past 5Y0.00% Gross Margin- 52W Low36.12% ATR (14)0.50
Dividend Ex-Date- Current Ratio15.03 EPS Y/Y TTM28.82% Oper. Margin0.00% RSI (14)45.60 Volatility5.26% 5.15%
Employees70 Debt/Eq0.05 Sales Y/Y TTM- Profit Margin- Recom1.40 Target Price31.11
Option/ShortYes / Yes LT Debt/Eq0.05 EPS Q/Q0.57% Payout- Rel Volume0.39 Prev Close8.94
Sales Surprise- EPS Surprise-18.63% Sales Q/Q- EarningsMay 09 AMC Avg Volume1.07M Price8.95
SMA201.00% SMA50-11.87% SMA200-20.49% Trades Volume418,463 Change0.11%
Date Action Analyst Rating Change Price Target Change
Apr-22-24Resumed BofA Securities Buy $30
Jan-12-24Downgrade RBC Capital Mkts Outperform → Sector Perform $24 → $15
Oct-10-23Downgrade Oppenheimer Outperform → Perform
Aug-28-23Initiated UBS Buy $36
Jun-13-23Initiated Evercore ISI Outperform $49
May-12-22Upgrade Raymond James Outperform → Strong Buy $33 → $12
Dec-20-21Initiated H.C. Wainwright Buy $46
Oct-26-21Resumed Cantor Fitzgerald Overweight $49
Jul-29-21Resumed BTIG Research Buy $60
May-25-21Downgrade Raymond James Strong Buy → Outperform $65 → $35
May-14-24 08:00AM
May-10-24 04:05PM
May-09-24 10:54PM
11:56PM Loading…
May-08-24 11:56PM
May-06-24 12:00PM
May-02-24 04:05PM
Apr-17-24 04:05PM
Apr-05-24 04:05PM
Apr-03-24 07:01PM
Mar-27-24 08:00AM
Mar-18-24 07:00AM
Mar-13-24 07:07AM
08:00AM Loading…
Mar-12-24 08:00AM
Mar-08-24 04:05PM
Mar-07-24 01:34PM
Mar-05-24 04:05PM
Mar-04-24 04:04PM
Mar-02-24 04:31AM
Feb-29-24 04:05PM
Feb-22-24 03:55AM
Feb-06-24 04:05PM
Feb-05-24 04:05PM
Jan-18-24 09:35AM
09:55AM Loading…
Jan-10-24 09:55AM
Dec-19-23 04:05PM
Dec-12-23 07:30AM
Dec-07-23 07:00AM
Dec-06-23 04:36PM
Dec-04-23 07:00AM
Nov-27-23 08:00AM
Nov-21-23 04:01PM
Nov-12-23 12:15PM
Nov-09-23 07:28AM
Nov-08-23 04:01PM
Oct-17-23 08:00AM
Oct-11-23 03:49AM
Oct-10-23 04:13PM
Oct-03-23 04:05PM
Sep-21-23 08:00AM
Sep-20-23 08:00AM
Sep-05-23 08:00AM
Aug-09-23 04:01PM
Jul-12-23 04:30PM
Jul-07-23 09:40AM
Jun-24-23 05:05AM
Jun-07-23 04:05PM
May-29-23 09:35AM
May-23-23 08:00AM
May-13-23 08:53AM
May-05-23 09:55AM
May-04-23 04:05PM
May-02-23 08:00AM
Apr-29-23 08:25AM
Apr-13-23 09:55AM
Apr-02-23 08:27AM
Mar-24-23 10:57AM
Mar-22-23 04:16PM
Mar-21-23 05:10PM
Mar-15-23 09:55AM
Mar-10-23 08:00AM
Mar-04-23 01:30PM
Feb-21-23 08:00AM
Feb-08-23 08:00AM
Jan-24-23 09:28AM
Jan-22-23 09:21AM
Jan-04-23 04:01PM
Dec-12-22 06:30PM
Nov-25-22 04:04AM
Nov-10-22 04:05PM
Nov-05-22 01:00PM
Oct-13-22 08:00AM
Sep-26-22 09:21AM
Sep-07-22 08:00AM
Sep-01-22 10:17AM
Aug-26-22 08:05AM
Aug-18-22 08:00AM
Aug-15-22 08:23AM
Aug-11-22 08:00AM
Jul-11-22 02:15PM
Jul-05-22 08:05AM
Jun-29-22 01:47AM
Jun-28-22 04:02PM
89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PALEKAR ROHANChief Executive OfficerApr 01 '24Option Exercise1.9325,00048,250511,889Apr 03 04:01 PM
PALEKAR ROHANChief Executive OfficerApr 01 '24Sale10.9152,718575,153459,171Apr 03 04:01 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 04 '24Buy15.351,350,00020,722,50012,431,584Mar 06 05:40 PM
PALEKAR ROHANChief Executive OfficerFeb 26 '24Sale10.764,47748,173486,889Feb 28 06:43 PM
PALEKAR ROHANChief Executive OfficerDec 29 '23Option Exercise1.9350,00096,500351,225Jan 03 04:54 PM
PALEKAR ROHANChief Executive OfficerDec 29 '23Sale11.2050,000560,000301,225Jan 03 04:54 PM
LAPORTE KATHLEENDirectorJul 17 '23Option Exercise2.6412,50033,00012,500Jul 18 06:04 PM
LAPORTE KATHLEENDirectorJul 17 '23Sale18.8012,500235,0000Jul 18 06:04 PM
PALEKAR ROHANChief Executive OfficerJun 05 '23Option Exercise1.9315,00028,950301,978Jun 07 05:04 PM
PALEKAR ROHANChief Executive OfficerJun 05 '23Sale20.0015,000300,000286,978Jun 07 05:04 PM
Atkinson Edward Morrow IIIDirectorJun 01 '23Option Exercise2.616,25016,3126,250Jun 05 05:03 PM
Atkinson Edward Morrow IIIDirectorJun 01 '23Sale17.916,250111,9380Jun 05 05:03 PM